Drug intelligence / Profile preview

Ir-rhod

Development stage: Preclinical
Modality: Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules

Overview

Ir-rhod is a mitochondria-targeted iridium complex coordinated with rhodamine, developed as an experimental anticancer agent. It is designed to overcome cisplatin resistance in cancer cells, particularly non-small cell lung cancer. The compound induces tumor cell death by disrupting mitochondrial function, triggering both apoptosis and ferroptosis pathways. Preclinical studies indicate that Ir-rhod’s targeting effect reduces systemic toxicity and enhances biosafety compared to non-targeted agents[6]. Its mechanism involves regulation of mitochondrial function and induction of regulated cell death processes.

Targets

GPX4 (Glutathione peroxidase 4)ACSL4 (Acyl-CoA synthetase long-chain family member 4)

Beyond the preview

Go deeper on Ir-rhod.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ir-rhod.

Explore the full profile